BNP Paribas Financial Markets’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-3,693
| Closed | -$8.42K | – | 4263 |
|
|
2024
Q2 | $8.42K | Buy |
3,693
+3,385
| +1,099% | +$12.9K | ﹤0.01% | 3739 |
|
|
2024
Q1 | $1.33K | Hold |
308
| – | – | ﹤0.01% | 3843 |
|
|
2023
Q4 | $939 | Sell |
308
-326
| -51% | -$613 | ﹤0.01% | 3855 |
|
|
2023
Q3 | $913 | Sell |
634
-6,893
| -92% | -$13.3K | ﹤0.01% | 3749 |
|
|
2023
Q2 | $18.7K | Sell |
7,527
-55,960
| -88% | -$153K | ﹤0.01% | 3589 |
|
|
2023
Q1 | $170K | Buy |
63,487
+28,472
| +81% | +$137K | ﹤0.01% | 3200 |
|
|
2022
Q4 | $190K | Sell |
35,015
-7,382
| -17% | -$61.9K | ﹤0.01% | 3016 |
|
|
2022
Q3 | $530K | Buy |
42,397
+40,264
| +1,888% | +$460K | ﹤0.01% | 2939 |
|
|
2022
Q2 | $10.5K | Sell |
2,133
-1,357
| -39% | -$7.51K | ﹤0.01% | 3744 |
|
|
2022
Q1 | $26.5K | Sell |
3,490
-35,893
| -91% | -$340K | ﹤0.01% | 3682 |
|
|
2021
Q4 | $402K | Buy |
39,383
+31,611
| +407% | +$403K | ﹤0.01% | 3107 |
|
|
2021
Q3 | $104K | Buy |
7,772
+6,430
| +479% | +$105K | ﹤0.01% | 3261 |
|
|
2021
Q2 | $29.4K | Sell |
1,342
-7,771
| -85% | -$173K | ﹤0.01% | 3435 |
|
|
2021
Q1 | $219K | Buy |
9,113
+4,807
| +112% | +$112K | ﹤0.01% | 3000 |
|
|
2020
Q4 | $77.5K | Sell |
4,306
-3,703
| -46% | -$55.3K | ﹤0.01% | 3339 |
|
|
2020
Q3 | $92.5K | Buy |
8,009
+4,760
| +147% | +$78.6K | ﹤0.01% | 3161 |
|
|
2020
Q2 | $78.8K | Sell |
3,249
-14,224
| -81% | -$235K | ﹤0.01% | 2864 |
|
|
2020
Q1 | $193K | Buy |
17,473
+13,204
| +309% | +$247K | ﹤0.01% | 2878 |
|
|
2019
Q4 | $113K | Sell |
4,269
-1,125
| -21% | -$26.3K | ﹤0.01% | 3241 |
|
|
2019
Q3 | $123K | Buy |
5,394
+2,549
| +90% | +$80.3K | ﹤0.01% | 3010 |
|
|
2019
Q2 | $87.2K | Sell |
2,845
-2,253
| -44% | -$47.4K | ﹤0.01% | 3109 |
|
|
2019
Q1 | $84.6K | Buy |
5,098
+4,787
| +1,539% | +$90.8K | ﹤0.01% | 3227 |
|
|
2018
Q4 | $5.96K | Sell |
311
-659
| -68% | -$24.7K | ﹤0.01% | 3522 |
|
|
2018
Q3 | $50.7K | Buy |
970
+303
| +45% | +$16.5K | ﹤0.01% | 3033 |
|
|
2018
Q2 | $29K | Sell |
667
-2,168
| -76% | -$92.9K | ﹤0.01% | 3344 |
|
|
2018
Q1 | $105K | Buy |
2,835
+1,045
| +58% | +$27.9K | ﹤0.01% | 3151 |
|
|
2017
Q4 | $35.5K | Buy |
1,790
+1,343
| +300% | +$28.9K | ﹤0.01% | 3817 |
|
|
2017
Q3 | $11.1K | Buy |
+447
| New | +$8.26K | ﹤0.01% | 3842 |
|
BNP Paribas Financial Markets's GTHX Position: Q3 2024 in Review
BNP Paribas Financial Markets sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 3,693 shares — an estimated $8.42K sold.
BNP Paribas Financial Markets first reported a position in GTHX in Q3 2017 and held it in 28 quarters. The position peaked at $530K in Q3 2022. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.
- BNP Paribas Financial Markets reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
- BNP Paribas Financial Markets sold 3,693 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $8.42K.
- BNP Paribas Financial Markets first reported a position in G1 Therapeutics, Inc. Common Stock in Q3 2017 and held it in 28 quarters.
- BNP Paribas Financial Markets's G1 Therapeutics, Inc. Common Stock position peaked at $530K in Q3 2022.
- 0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.
Based on BNP Paribas Financial Markets's 13F filing for Q3 2024, filed 13 Nov 2024.